U.S. Insomnia Market by Non-Pharmacological Therapy (CBTI, Hypnotherapy), Prescription Sleep Aids (Benzodiazepines, Non-Benzodiazepines (Zaleplon), Orexin Antagonist) & OTC Treatment (Antihistamine, Melatonin, Valerian Root)) - Forecasts to 2021
[144 Pages Report] The U.S. insomnia market is projected to reach USD 4.24 Billion by 2021 from USD 3.38 Billion in 2016, at a CAGR of 4.6% during the forecast period. In this report, the U.S. insomnia market is segmented on the basis of type of treatment.
Based on type of treatment, the U.S. insomnia market is categorized into pharmacological treatments and non-pharmacological treatments. The pharmacological treatments segment is further categorized into prescription sleep aids and over-the-counter sleep aids. The over-the-counter sleep aids segment is estimated to grow at the highest CAGR during the forecast period due to easier availability and low price as compared to prescription sleep aids. Moreover, according to consumer reports, a patient can save up to USD 47 a week using OTC sleep aids.
Based on non-pharmacological treatment, the market is categorized into cognitive behavioural therapy for insomnia (CBTI), hypnotherapy, and other alternative therapies. CBTI is highly recommended therapy for insomnia patients due as its can be used with multiple approaches that enables physicians to understand and cure patients comprehensibly. The other alternative therapies include exercise/yoga, acupuncture, biofeedback, bright light therapy, music therapy, and aroma therapy.
The prescription sleep aids market is segmented into non-benzodiazepines, benzodiazepines, orexin antagonists, melatonin receptor agonist, and other prescription sleep aids. The non-benzodiazepines segment is further categorized into zolpidem, eszopiclone, and zaleplon. In 2016, zolpidem is expected to account for the largest share of the non-benzodaizepines market for insomnia. However, higher adoption of generic products that are available are cheaper price is negatively affecting the growth of the market. Other prescription sleep aids include sleep aids such as antipsychotics, chloral derivatives, and tricyclic antidepressants.
Key players operating in the U.S. insomnia market are Eisai, Co. Ltd. (Japan), Merck & Co., Inc. (U.S.), Meda Consumer Healthcare Inc. (U.S.), Pfizer, Inc. (U.S.), Sanofi (France), Takeda Pharmaceutical Company Ltd. (Japan), Pernix Therapeutics (U.S.), and Purdue Pharma L.P. (U.S.).
Target Audience:
|
S. NO. |
TYPE OF THERAPY |
KEY INFLUENCERS |
|
1 |
Prescription Sleep Aids |
Primary Care Physicians (PCP) and Psychiatrists |
|
2 |
Cognitive Behavioral Therapy for Insomnia |
Psychiatrists/ Psychotherapists, Psychologists, Sleep Technicians, Sleep Counselors/ Consultants, and Clinical Social Workers/Therapists |
|
3 |
Hypnotherapy |
Hypnotherapists, Hypnotists, Psychologists, and Psychiatrists |
|
4 |
Exercise/Yoga |
Physicians, Sleep Counselors/ Consultants, Clinical Social Workers/Therapists, and Exercise and Yoga Instructors |
|
5 |
Acupuncture |
Sleep Counselors/Consultants and Primary Care Physicians (PCP) |
|
6 |
Biofeedback |
Psychiatrists/Psychotherapists and Psychologists |
To know about the assumptions considered for the study, download the pdf brochure
Want to explore hidden markets that can drive new revenue in U.S. Insomnia Market?
Particular |
Scope |
|
Country |
|
|
Historical Years |
2013-2014 |
|
Base Year |
2015 |
|
Estimated Year |
2016 |
|
Forecast Period |
2016–2021 |
|
Revenue Currency |
USD |
Market Segmentation
U.S. Insomnia Market, by Treatment
- Pharmacological Treatments
- Non-pharmacological Treatments
U.S. Insomnia Market, by Pharmacological Treatment
- Prescription Sleep Aids
- Over-the-Counter Sleep Aids
U.S. Insomnia Market, by Prescription Sleep Aids
- Non-benzodiazepines
- Zolpidem
- Eszopiclone
- Zaleplon
- Benzodiazepines
- Orexin Antagonists
- Melatonin Receptor Antagonists
- Other Prescription Sleep Aids
U.S. Insomnia Market, by Over-the-Counter Sleep Aids
- Antihistamines
- Melatonin
- Valerian Roots
- Other Herbal & Dietary Supplements
U.S. Insomnia Market, by Non-pharmacological Treatment
- Cognitive Behavioral Therapy for Insomnia (CBTI)
- Hypnotherapy
- Other Alternative Therapies
Available Customizations
With the given market data, MarketsandMarkets offers customizations as per the company‘s specific needs. The following customization options are available for the report:
Geographic Analysis
- Analysis of the insomnia market for other key regions/countries
Company Information
- Detailed analysis and profiling of additional market players (up to five)
The U.S. insomnia market is categorised into pharmacological treatments and non-pharmacological treatments. The U.S. insomnia pharmacological treatment market is projected to reach USD 4.24 Billion by 2021 from USD 3.38 Billion in 2016, growing at a CAGR of 4.6% from 2016 to 2021. The duration of insomnia can be from a day to years. Based on duration, insomnia is divided into three major categories, namely, transient insomnia (less than a month), short term insomnia (between 1 month and 6 months), and chronic insomnia (more than 6 months).
The non-pharmacological treatment market is categorized into cognitive behavioural therapy for insomnia (CBTI), hypnotherapy, and other alternative therapies. CBTI is highly recommended therapy for insomnia patients followed by hypnotherapy due as its can be used with multiple approaches that enables physicians to understand and cure patients comprehensibly. The other alternative therapies includes exercise/yoga, acupuncture, biofeedback, bright light therapy, music therapy, and aroma therapy.
The pharmacological treatment market is further segmented into prescription sleep aids and over-the-counter sleep aids. In 2016, the prescription sleep aids segment is expected to hold the largest share of the U.S. insomnia pharmacological treatment market. The launch of Belsomra (Merck & Co., Inc) in 2014 in the U.S. and the anticipated launch of E-2006 (Eisai Co., Ltd.) is expected to drive the growth of the market during the forecast years. The prescription sleep aids segment is categorised into non-benzodiazepines, benzodiazepines, orexin antagonists, melatonin receptor agonists, and other prescription sleep aids. Other prescription sleep aids include sleep aids such as antipsychotics, chloral derivatives, and tricyclic antidepressants. The non-benzodiazepines segment is further categorized into zolpidem, eszopiclone, and zaleplon.
The over-the-counter sleep aids segment of U.S. insomnia pharmacological treatment market is expected to grow at the highest CAGR during the forecast period. Reasons attributing to the growth of this market includes easier availability, low prices, and publicity regarding the side effects of the prescription sleep aids has also steered the patients towards OTC sleep aid. The OTC sleep aids market is categorised into antihistamines, melatonin, valerian roots, and other herbal & dietary supplements. Other herbal & dietary supplements include sleep aids such as L-theanine, amino acids supplements, and a variety of botanicals. Growing awareness about the advantages of melatonin and valerian roots such as least amount of side effects, reduces stress levels, and its growing consumption is driving the growth of this segment in the U.S.
Eisai, Co. Ltd. (Japan), Merck & Co., Inc. (U.S.), Meda Consumer Healthcare Inc. (U.S.), Pfizer, Inc. (U.S.), Sanofi (France), Takeda Pharmaceutical Company Ltd. (Japan), Pernix Therapeutics (U.S.), and Purdue Pharma L.P. (U.S.) are some of the leading players operating in the U.S. insomnia market.
To speak to our analyst for a discussion on the above findings, click Speak to Analyst
Exclusive indicates content/data unique to MarketsandMarkets and not available with any competitors.
Table of Contents
1 Introduction
1.1 Objectives of the Study
1.2 Market Definition
1.2.1 Markets Covered
1.2.2 Years Considered for the Study
1.3 Currency
1.4 Limitations
1.5 Key Stakeholders/Influencers
2 Research Methodology
2.1 Market Size Estimation – Non-Pharmacological Treatments Market
2.1.1 Market Breakdown and Data Triangulation
2.1.2 Key Data From Secondary Sources
2.1.3 Key Data From Primary Sources
2.2 Market Size Estimation – Pharmacological Treatments Market
2.2.1 Market Forecast Model
2.2.2 Market Size Estimation
2.2.3 Market Breakdown and Data Triangulation
2.2.4 Key Data From Primary and Secondary Sources
2.3 Research Assumptions
3 Executive Summary
4 Premium Insights
4.1 Physicians Views About Cognitive Behavioral Therapy for Insomnia (CBTI)
4.2 Age-Wise Commonly Used/Prescribed Treatments for Each Type of Insomnia
4.3 List of Ongoing Phase-III Clinical Trails for Insomnia
4.4 U.S. Insomnia Market: Consumer Selection Criteria
5 Market Overview
5.1 Introduction
5.2 Market Dynamics
5.2.1 Market Drivers
5.2.1.1 Government Support to Control Rising Insomnia Cost
5.2.1.2 OTC Sleep Aids to Drive the Pharmacological Treatment Market Growth
5.2.2 Market Restraints
5.2.2.1 Erosion in Branded Prescription Sleep Aid Sales Due to Growing Adoption of Generics
5.2.2.2 Side Effects of Benzodiazepine and Non-Benzodiazepine Drugs
5.2.2.3 Non Pharmacological Therapies to Restrict the Growth of Drugs Market
5.2.3 Market Opportunities
5.2.3.1 Unmet Need for More Effective and Safe Drugs
5.2.3.2 Presence of Large Insomnia Population Pool
6 Non-Pharmacological Treatment Market
6.1 Introduction
6.1.1 Cognitive Behavioral Therapy for Insomnia (CBTI)
6.1.2 Hypnotherapy
6.1.3 Other Alternative Therapies
6.2 Therapy Recommendation, 2015 (%)
6.3 Qualitative Assessment
7 Pharmacological Treatment Market
7.1 Introduction
7.2 U.S.: Insomnia Pharmacological Treatment Market Size, By Type
7.2.1 U.S.: Prescription Sleep Aids Market Size for Insomnia
7.2.1.1 U.S.: Prescription Sleep Aids Market Size for Insomnia, By Type
7.2.1.1.1 U.S.: Non- Benzodiazepine Sleep Aids Market Size for Insomnia, By Type
7.2.2 U.S.: Over-The-Counter (OTC) Sleep Aids Market Size for Insomnia, By Type
8 Competitive Landscape
8.1 Key Players in the U.S. Insomnia Pharmacological Treatment Market
8.2 Top Available Mobile Applications for Insomnia
8.3 Corporate Strategies Followed Within U.S. Insomnia Market
8.4 Competitive Situations & Trends
8.4.1 Product Launches & Approvals
8.4.2 Collaborations, Agreements and Partnerships
8.4.3 Acquisitions
9 Company Profiles
9.1 Introduction
9.2 Merck & Co., Inc.
9.3 Eisai Co., Ltd.
9.4 Meda Consumer Healthcare, Inc
9.5 Takeda Pharmaceuticals Company Ltd.
9.6 Pfizer Inc.
9.7 Sanofi
9.8 Vanda Pharmaceuticals
9.9 Pernix Therapeutics
9.10 Purdue Pharmaceuticals L.P.
10 Appendix
10.1 Discussion Guide
10.2 Related Reports
10.3 Related Reports
10.4 Knowledgestore Subscription Portal
10.5 MnM Knowledgestore: Snapshot
10.6 RT: Real-Time Market Intelligence
10.7 Disclaimer
10.8 Author Details
List of Tables (16 Tables)
Table 1 Key Stakeholders/Influencers for Diagnosed Insomnia Patients
Table 2 Physicians Views About Cognitive Behavioral Therapy for Insomnia (CBTI)
Table 3 Age-Wise Commonly Used/Prescribed Treatments for Each Type of Insomnia
Table 4 List of Ongoing Phase-III Clinical Trails for Insomnia
Table 5 Insomnia Treatment Selection Criteria: Impact Analysis
Table 6 U.S. Insomnia Market, By Non-Pharmacological Treatment (Qualitative Assessment)
Table 7 U.S.: Insomnia Pharmacological Treatment Market Size , By Type, 2013-2021 (USD Million)
Table 8 U.S.: Insomnia Pharmacological Treatment Market Size , By Prescription Sleep Aids, 2013-2021 (USD Million)
Table 9 U.S.: Prescriptions Sleep Aids Market Size for Insomnia, By Type, 2013-2021 (USD Million)
Table 10 U.S.: Non- Benzodiazepine Sleep Aids Market Size for Insomnia, By Type, 2013-2021 (USD Million)
Table 11 U.S.: Over-The-Counter (OTC) Sleep Aids Market Size for Insomnia, By Type, 2013-2021 (USD Million)
Table 12 Key Players in the U.S. Insomnia Pharmacological Treatment Market (2016)
Table 13 Top Available Mobile Applications for Insomnia (2016)
Table 14 Product Launches and Approvals, 2013 –2016
Table 15 Collaborations, Agreements and Partnerships 2013–2016
Table 16 Acquisitions, 2013–2016
List of Figures (33 Figures)
Figure 1 Segmentation & Coverage
Figure 2 Prevalence of Insomnia, By Type (2012-2015)
Figure 3 Research Design – Non-Pharmacological Treatments Market
Figure 4 Market Breakdown and Data Triangulation – Non-Pharmacological Treatments Market
Figure 5 Forecasting Model– Pharmacological Treatments Market
Figure 6 Market Size Estimation – Pharmacological Treatments Market
Figure 7 Market Breakdown and Data Triangulation – Pharmacological Treatments Market
Figure 8 Assumptions for the Study
Figure 9 Market Scope
Figure 10 Pharmacological Treatment Market Share, By Type (2014-2021)
Figure 11 U.S. Insomnia Market: Consumer Selection Criteria
Figure 12 U.S. Insomnia Market: Drivers, Restraints, and Opportunities
Figure 13 U.S. Insomnia Market, By Non-Pharmacological Treatment, Therapy Recommendation, 2015 (%)
Figure 14 U.S. Insomnia Pharmacological Treatment Market Segmentation
Figure 15 U.S.: Insomnia Pharmacological Treatment Market, 2013-2021 (USD Million)
Figure 16 Market Share: Pharmacological Treatment Market (2016)
Figure 17 Market Share: Prescription Sleep Aids Market (2016)
Figure 18 U.S. Insomnia Prescription Sleep Aids Market Snapshot
Figure 19 Market Share: Non-Benzodiazepine Sleep Aids Market (2016)
Figure 20 Market Share: Non-Benzodiazepine Sleep Aids Market (2016)
Figure 21 U.S.: Over-The-Counter (OTC) Sleep Aids Market Snapshot
Figure 22 Battle for Market Share: Product Launches and Approvals—Key Strategies Adopted By Market Players (2013-2016)
Figure 23 Geographic Revenue Mix of Major Players in the U.S. Insomnia Market (2016)
Figure 24 Sumitomo Dainippon Pharma Co., Ltd.: Company Snapshot (2015)
Figure 25 Sanofi: Company Snapshot (2015)
Figure 26 Pfizer Inc: Company Snapshot (2015)
Figure 27 Takeda Pharmaceutical Company Ltd.: Company Snapshot (2015)
Figure 28 Merck & Co., Inc.: Company Snapshot (2015)
Figure 29 Meda Consumer Healthcare Inc.: Company Snapshot (2015)
Figure 30 Eisai Co., Ltd.: Company Snapshot (2015)
Figure 31 Purdue Pharmaceuticals L.P.: Company Snapshot (2015)
Figure 32 Pernix Therapeutics: Company Snapshot (2015)
Figure 33 Vanda Pharmaceuticals: Company Snapshot (2015)
Generating Response ...
Growth opportunities and latent adjacency in U.S. Insomnia Market